Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions.
Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics:
- E: The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle
- S: Ability to boost R&D productivity through operational optimization and process transformation
- G: Promote ethical conduct of business and collaboration while ensuring inclusion & diversity
What We Do
- Invest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D.
- Streamline the product-market fit and ensure access to supportive infrastructure and resources.
- Facilitate their collaborative R&D/commercialization strategy in geographies of interest.
How We Do It
Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by:
- Reducing costs through infrastructure consolidation and collaborative expertise
- Expanded access to capital
- Facilitating rapid market penetration and commercial scaling